| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.89▲ | 1.93▲ | 1.94▲ | 1.69▲ | 1.72▲ |
| MA10 | 1.91▲ | 1.92▲ | 1.81▲ | 1.60▲ | 1.75▲ |
| MA20 | 1.91▲ | 1.76▲ | 1.64▲ | 1.71▲ | 1.97▼ |
| MA50 | 1.70▲ | 1.53▲ | 1.54▲ | 1.79▲ | 1.36▲ |
| MA100 | 1.51▲ | 1.59▲ | 1.69▲ | 2.00▼ | 1.04▲ |
| MA200 | 1.56▲ | 1.68▲ | 1.79▲ | 1.52▲ | 1.48▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.014▼ | 0.005▲ | 0.045▲ | 0.043▲ | -0.091▼ |
| RSI | 63.122▲ | 70.315▲ | 68.880▲ | 58.413▲ | 52.889▲ |
| STOCH | 29.044 | 69.412 | 93.342▲ | 57.957 | 30.007 |
| WILL %R | -29.412 | -14.085▲ | -7.813▲ | -6.024▲ | -47.297 |
| CCI | 68.827 | 82.781 | 74.670 | 112.317▲ | -57.026 |
|
Thursday, August 07, 2025 01:26 PM
IN8bio is developing a platform of cell therapies using gamma-delta T cells, a type of immune cell believed to help target and destroy cancer cells. Its current lead programs include INB-200 for ...
|
|
Tuesday, March 18, 2025 05:12 AM
IN8bio, Inc., a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies for cancer and autoimmune diseases, will participate in the Immuno-Oncology 360° Conference 2025 from ...
|
|
Thursday, March 13, 2025 01:30 PM
IN8BIO ($INAB) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.04 per share, beating estimates of -$0.08 by $0.04. The ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/12/25 | 1.91 | 1.95 | 1.83 | 1.95 | 42,407 |
| 24/12/25 | 1.74 | 2.00 | 1.71 | 2.00 | 287,323 |
| 23/12/25 | 1.55 | 1.79 | 1.35 | 1.75 | 519,454 |
| 22/12/25 | 1.21 | 1.58 | 1.20 | 1.55 | 758,175 |
| 19/12/25 | 1.46 | 1.48 | 1.17 | 1.21 | 10,753,526 |
| 18/12/25 | 1.41 | 1.41 | 1.32 | 1.38 | 74,539 |
| 17/12/25 | 1.50 | 1.50 | 1.38 | 1.42 | 51,065 |
| 16/12/25 | 1.55 | 1.565 | 1.445 | 1.50 | 74,040 |
| 15/12/25 | 1.72 | 1.7211 | 1.53 | 1.60 | 74,825 |
| 12/12/25 | 1.76 | 1.87 | 1.67 | 1.68 | 86,115 |
|
|
||||
|
|
||||
|
|